No Burning Desire for Valeant’s Female Arousal Drug: Chart

Sales of Valeant Pharmaceuticals International Inc.’s female libido pill Addyi have been falling since the company was said to cut the drug’s sales force. There have been concerns about the treatment’s effectiveness, its side effects -- including fainting -- as well as its price and coverage by health insurers since sales began in October. Valeant believes Addyi has strong potential and is building a new internal sales force, Tracy Valorie, general manager of women’s health at the company, said in an e-mail.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.